ArticleCureus2026
Beyond the Bone Marrow: A Case Report of Extramedullary Hematopoiesis in Advanced Primary Myelofibrosis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis, cytopenias, splenomegaly, and extramedullary hematopoiesis (EMH). Although EMH most commonly involves the spleen and liver, extensive organ infiltration leading to portal hypertension and obstructive cholestasis is uncommon. We present the case of a 54-year-old man diagnosed with PMF who developed massive hepatosplenic EMH following prolonged interruptions to treatment caused by barriers to healthcare access. The disease progressed to an accelerated phase with extensive bone marrow fibrosis, grade 3 osteosclerosis, and 10.5% aberrant myeloid blasts without fulfilling diagnostic criteria for acute myeloid leukemia. Imaging demonstrated diffuse periportal infiltrative soft tissue causing biliary obstruction, massive splenomegaly, portal hypertension, and esophagogastric varices. The patient received hydroxyurea, ruxolitinib, and palliative hepatosplenic radiotherapy, achieving transient clinical and biochemical improvement. However, he subsequently developed radiation-induced bone marrow aplasia and died from progressive disease. This case underscores the aggressive clinical course of advanced PMF when continuous disease-modifying therapy is interrupted and highlights the importance of timely access to targeted treatment and a multidisciplinary approach for managing extensive EMH and its life-threatening complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.